Henrar RE - Search Results

1

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

Nuijen B, Bouma M, Henrar RE, Brauns U, Bette P, Bult A, Beijnen JH. Nuijen B, et al. Among authors: henrar re. Int J Pharm. 2000 Jan 25;194(2):261-7. doi: 10.1016/s0378-5173(99)00389-0. Int J Pharm. 2000. PMID: 10692650

2

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

Nuijen B, Bouma M, Henrar RE, Manada C, Bult A, Beijnen JH. Nuijen B, et al. Among authors: henrar re. Anticancer Drugs. 1999 Nov;10(10):879-87. doi: 10.1097/00001813-199911000-00003. Anticancer Drugs. 1999. PMID: 10630355

3

Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).

Jonkman-de Vries JD, de Graaff-Teulen MJ, Henrar RE, Kettenes-van den Bosch JJ, Bult A, Beijnen JH. Jonkman-de Vries JD, et al. Among authors: henrar re. Invest New Drugs. 1994;12(4):303-14. doi: 10.1007/BF00873045. Invest New Drugs. 1994. PMID: 7775131

4

Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.

Jonkman-de Vries JD, Talsma H, Henrar RE, Kettenes-van den Bosch JJ, Bult A, Beijnen JH. Jonkman-de Vries JD, et al. Among authors: henrar re. Cancer Chemother Pharmacol. 1994;34(5):416-22. doi: 10.1007/BF00685567. Cancer Chemother Pharmacol. 1994. PMID: 8070009

5

The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).

Jonkman-De Vries JD, Rosing H, Henrar RE, Bult A, Beijnen JH. Jonkman-De Vries JD, et al. Among authors: henrar re. PDA J Pharm Sci Technol. 1995 Nov-Dec;49(6):283-8. PDA J Pharm Sci Technol. 1995. PMID: 8581459

6

Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244).

Vries JD, Doppenberg WG, Henrar RE, Bult A, Beijnen JH. Vries JD, et al. Among authors: henrar re. J Pharm Sci. 1996 Nov;85(11):1227-33. doi: 10.1021/js960005n. J Pharm Sci. 1996. PMID: 8923330

7

Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.

Jonkman-de Vries JD, Van den Bemt BJ, ten Bokkel-Huinink WW, Underberg WJ, Kettenes-van den Bosch JJ, Henrar RE, Bult A, Beijnen JH. Jonkman-de Vries JD, et al. Among authors: henrar re. PDA J Pharm Sci Technol. 1997 Mar-Apr;51(2):89-95. PDA J Pharm Sci Technol. 1997. PMID: 9146040

8

Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].

Jonkman-de Vries JD, Rosing H, Talsma H, Henrar RE, Kettenes-van den Bosch JJ, Bult A, Beijnen JH. Jonkman-de Vries JD, et al. Among authors: henrar re. Invest New Drugs. 1998;16(2):99-111. doi: 10.1023/a:1006041024109. Invest New Drugs. 1998. PMID: 9848573

9

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

Nuijen B, Bouma M, Henrar RE, Floriano P, Jimeno JM, Talsma H, Kettenes-van den Bosch JJ, Heck AJ, Bult A, Beijnen JH. Nuijen B, et al. Among authors: henrar re. PDA J Pharm Sci Technol. 2000 May-Jun;54(3):193-208. PDA J Pharm Sci Technol. 2000. PMID: 10927911

10

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.

Jonkman-de Vries JD, Kettenes-van den Bosch JJ, Henrar RE, Bult A, Beijnen JH. Jonkman-de Vries JD, et al. Among authors: henrar re. Invest New Drugs. 1996;14(2):181-91. doi: 10.1007/BF00210789. Invest New Drugs. 1996. PMID: 8913839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters